Bluebird bio Reports Third Quarter 2023 Financial Results an

- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 22 patient starts across both programs to date –


- Ended quarter with $227M in cash, cash equivalents, marketable securities and...

Related Keywords

Philadelphia , Pennsylvania , United States , Massachusetts , University Of Pennsylvania , Michigan , American , Andrew Obenshain , Janetl Kwiatkowski , Alexisa Thompson , Julie Kanter , Division Of Hematology , Department Of Pediatrics , Thalassemia Center , Nasdaq , Perelman School Of Medicine , Exchange Commission , Drug Administration , San Diego Convention Center , American Society Of Hematology , University Of Alabama , Sickle Cell Disease Center , Biologics Licensing Application , Priority Review , Prescription Drug User Fee Act , Rare Pediatric Disease Priority Review Voucher , American Society , Annual Meeting , Health Related Quality , Sickle Cell Disease , Who Have Received , Gene Therapy , Sickle Cell , Improved Quality , Pediatric Patients , Post Treatment , Perelman School , Iron Burden , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Priority Review Voucher , Consolidated Statements , Markets ,